201 related articles for article (PubMed ID: 30513968)
1. Rhabdoviruses, Antiviral Defense, and SUMO Pathway.
El Asmi F; Brantis-de-Carvalho CE; Blondel D; Chelbi-Alix MK
Viruses; 2018 Dec; 10(12):. PubMed ID: 30513968
[TBL] [Abstract][Full Text] [Related]
2. MxA Mediates SUMO-Induced Resistance to Vesicular Stomatitis Virus.
Maarifi G; Hannoun Z; Geoffroy MC; El Asmi F; Zarrouk K; Nisole S; Blondel D; Chelbi-Alix MK
J Virol; 2016 Jul; 90(14):6598-6610. PubMed ID: 27170750
[TBL] [Abstract][Full Text] [Related]
3. MxA interacts with and is modified by the SUMOylation machinery.
Brantis-de-Carvalho CE; Maarifi G; Gonçalves Boldrin PE; Zanelli CF; Nisole S; Chelbi-Alix MK; Valentini SR
Exp Cell Res; 2015 Jan; 330(1):151-63. PubMed ID: 25447205
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.
Li Z; Wu S; Wang J; Li W; Lin Y; Ji C; Xue J; Chen J
Int J Mol Med; 2012 Nov; 30(5):1053-60. PubMed ID: 22895527
[TBL] [Abstract][Full Text] [Related]
5. Interferon, restriction factors and SUMO pathways.
El-Asmi F; McManus FP; Thibault P; Chelbi-Alix MK
Cytokine Growth Factor Rev; 2020 Oct; 55():37-47. PubMed ID: 32591223
[TBL] [Abstract][Full Text] [Related]
6. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
[TBL] [Abstract][Full Text] [Related]
8. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection.
Balachandran S; Roberts PC; Brown LE; Truong H; Pattnaik AK; Archer DR; Barber GN
Immunity; 2000 Jul; 13(1):129-41. PubMed ID: 10933401
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Rhabdoviridae Infection and Subversion of Antiviral Responses.
Blondel D; Maarifi G; Nisole S; Chelbi-Alix MK
Viruses; 2015 Jul; 7(7):3675-702. PubMed ID: 26198243
[TBL] [Abstract][Full Text] [Related]
10. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus.
Osiak A; Utermöhlen O; Niendorf S; Horak I; Knobeloch KP
Mol Cell Biol; 2005 Aug; 25(15):6338-45. PubMed ID: 16024773
[TBL] [Abstract][Full Text] [Related]
11. Enhanced detection of in vivo SUMO conjugation by Ubc9 fusion-dependent sumoylation (UFDS).
Niedenthal R
Methods Mol Biol; 2009; 497():63-79. PubMed ID: 19107411
[TBL] [Abstract][Full Text] [Related]
12. SUMO and Cytoplasmic RNA Viruses: From Enemies to Best Friends.
El Motiam A; Vidal S; Seoane R; Bouzaher YH; González-Santamaría J; Rivas C
Adv Exp Med Biol; 2020; 1233():263-277. PubMed ID: 32274761
[TBL] [Abstract][Full Text] [Related]
13. Aging-related SUMOylation pattern in the cortex and blood plasma of wild type mice.
Ficulle E; Sufian MDS; Tinelli C; Corbo M; Feligioni M
Neurosci Lett; 2018 Mar; 668():48-54. PubMed ID: 29325714
[TBL] [Abstract][Full Text] [Related]
14. SUMO: getting it on.
Anckar J; Sistonen L
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1409-13. PubMed ID: 18031233
[TBL] [Abstract][Full Text] [Related]
15. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
[TBL] [Abstract][Full Text] [Related]
16. SUMO pathway components as possible cancer biomarkers.
Mattoscio D; Chiocca S
Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
[TBL] [Abstract][Full Text] [Related]
17. Rhabdovirus evasion of the interferon system.
Rieder M; Conzelmann KK
J Interferon Cytokine Res; 2009 Sep; 29(9):499-509. PubMed ID: 19715459
[TBL] [Abstract][Full Text] [Related]
18. Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity.
Li X; Zhang Q; Ding Y; Liu Y; Zhao D; Zhao K; Shen Q; Liu X; Zhu X; Li N; Cheng Z; Fan G; Wang Q; Cao X
Nat Immunol; 2016 Jul; 17(7):806-15. PubMed ID: 27240213
[TBL] [Abstract][Full Text] [Related]
19. Individual differentiation of innate antiviral immunity in humans; the role of endogenous interferons and tumor necrosis factor in the immunity of leukocytes.
Orzechowska B; Antoszków Z; Błach-Olszewska Z
Arch Immunol Ther Exp (Warsz); 2003; 51(1):51-60. PubMed ID: 12691304
[TBL] [Abstract][Full Text] [Related]
20. Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication.
Sahin U; Ferhi O; Carnec X; Zamborlini A; Peres L; Jollivet F; Vitaliano-Prunier A; de Thé H; Lallemand-Breitenbach V
Nat Commun; 2014 Jun; 5():4187. PubMed ID: 24942926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
